Sugi Predict

Sugi Predict / Compounds / SCHEMBL60004

SCHEMBL60004

SCHEMBL60004

NC1(C(=O)O)CCCc2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RAD52 P43351 1/20 0.55
▸ KDM4E B2RXH2 3/20 0.50
▸ KDM1A O60341 3/20 0.50
▸ MAPT P10636 2/20 0.50
▸ CYP2C19 P33261 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ GRM1 Q13255 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ CYP1A2 P05177 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ GRM2 Q14416 1/20 0.47
▸ AKR1C1 Q04828 1/20 0.46
▸ HDAC9 Q9UKV0 1/20 0.45
▸ AKR1B1 P15121 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11149959 0.98 RAD52 (0.53) RAD52KDM4EKDM1AMAPTCYP2C19
SCHEMBL197940 0.89 KDM4E (0.61) RAD52KDM4EKDM1AMAPTCYP2C19
SCHEMBL29380732 0.89 KDM4E (0.61) RAD52KDM4EKDM1AMAPTCYP2C19
SCHEMBL197941 0.89 KDM4E (0.61) RAD52KDM4EKDM1AMAPTCYP2C19
SCHEMBL197942 0.89 KDM4E (0.61) RAD52KDM4EKDM1AMAPTCYP2C19
Hydrochloric Acid SCHEMBL17604963 0.88 KDM4E (0.59) RAD52KDM4EKDM1AMAPTCYP2C19
Hydrochloric Acid SCHEMBL4835584 0.88 KDM4E (0.59) RAD52KDM4EKDM1AMAPTCYP2C19
Hydrochloric Acid SCHEMBL4835592 0.88 KDM4E (0.59) RAD52KDM4EKDM1AMAPTCYP2C19
Hydrochloric Acid SCHEMBL11788510 0.83 KDM1A (0.47) RAD52KDM1AALDH1A1BLMMEN1
SCHEMBL9433786 0.81 KDM1A (0.49) KDM1AMAPTALDH1A1MEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129092-B2 Resist pattern thickening material and process for forming resist pattern, and semiconductor device and method for manufacturing the same FUJITSU LIMITED (JP) 2012-03-06 — — US claimed
US-20040122013-A1 Analogs of nocicettin ITALFARMACO SPA (IT) 2004-06-24 — — US claimed
EP-1422240-A2 Analogs of nociceptin ITALFARMACO S.p.A. (IT) 2004-05-26 — — EP claimed
CN-104703964-B Substituted aminoindane- and aminotetralincarboxylic acids and use thereof 拜耳制药股份公司 2017-04-12 — — CN disclosed
CN-104703964-B Substituted aminoindane- and aminotetralincarboxylic acids and use thereof 拜耳制药股份公司 2017-04-12 — — CN disclosed
US-9387203-B2 Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-07-12 — — US disclosed
US-9387203-B2 Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-07-12 — — US disclosed
US-9387203-B2 Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-07-12 — — US disclosed
US-20150218538-A1 Methods and Compositions for Modulating G-Alpha-Q Signaling NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-08-06 — — US disclosed
US-20150174113-A1 SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND THE USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 — — US disclosed
US-20150174113-A1 SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND THE USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 — — US disclosed
US-20040122013-A1 Analogs of nocicettin ITALFARMACO SPA (IT) 2004-06-24 — — US disclosed
EP-1422240-A2 Analogs of nociceptin ITALFARMACO S.p.A. (IT) 2004-05-26 — — EP disclosed
EP-0625164-A1 CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-11-23 — — EP disclosed
WO-1993007170-A1 CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-04-15 — — WO disclosed
EP-0028485-B1 SPIRO-IMIDAZOLONES FOR ALLEVIATING DIABETES-ASSOCIATED CONDITIONS, PROCESSES FOR PREPARING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER INC. (US) 1983-08-24 — — EP disclosed
US-4283409-A ANTIDIABETIC AGENTS PFIZER INC. (US) 1981-08-11 — — US disclosed
EP-0028485-A1 Spiro-imidazolones for alleviating diabetes-associated conditions, processes for preparing them, and pharmaceutical compositions containing them PFIZER INC. (US) 1981-05-13 — — EP disclosed
US-4061628-A Intermediates for producing semi-synthetic penicillins and cephalosporins and methods of production AMERICAN HOME PRODUCTS CORPORATION (US) 1977-12-06 — — US disclosed
US-3997532-A Intermediates for producing semi-synthetic cephalosporins AMERICAN HOME PRODUCTS CORPORATION (US) 1976-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150174113-A1 SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND THE USE THEREOF AADAT, DDC, AASDHPPT RAD52 3755/4885KDM4E 3492/4885KDM1A 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.